Search Articles
SAN FRANCISCO – Impax Laboratories propped up its stock price with false and misleading statements about its Rytary drug, and the share price dropped from $20 to $14.80 when the truth came out, a shareholder claims in a federal class action.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.